<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000513068">
  <TermName>Amplimexon</TermName>
  <TermPronunciation>(AM-plih-MEK-son)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance that is being studied in the treatment of some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma. It belongs to the family of drugs called cyanoaziridine derivatives. Also called imexon.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000718478" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Amplimexon&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000718477" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Amplimexon&quot;" language="es" id="_4"/>
  <SpanishTermName>Amplimexon</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento de algunos tipos de cáncer, como el cáncer de páncreas, de pulmón, de seno (mama) y de próstata, el melanoma y el mieloma múltiple. Es un tipo de derivado de la cianoaziridina. También se llama imexón.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2006-10-21</DateFirstPublished>
</GlossaryTerm>
